[1] 中国心血管健康与疾病报2022编写组. 中国心血管健康与疾病报告2022要点解读[J]. 中国心血管杂志,2023,28(4):297-312.
[2] 李宪伦,王显,吴永健,等. 经皮冠状动脉介入术后中西医结合心脏康复专家共识[J]. 中国康复医学杂志,2022,37(11):1517-1528.
[3] CHANG J G. PLAC test for Lp-PLA2 activity to predict coronary heart disease[J]. Am Fam Physician,2020,101(1):44-46.
[4] ZHANG H,GAO Y,WU D,et al. The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease[J]. BMC Cardiovasc Disord,2020,20(1):295.
[5] WANG R,WANG X,ZHANG E,et al. Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease[J]. Am J Transl Res, 2021,13(8):8997-9004.
[6] 刘亚东,马利军,杨延星. 冠心病病人冠状动脉斑块性质与 Lp-PLA2、Hcy和 D-二聚体水平的相关性分析[J]. 中西医结合心脑血管病杂志,2020,18(7):1100-1102.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J]. 中华心血管病杂志,2017,45(5):359-376.
[8] 胡龙,黄政,章敬水,等. 多功能5F tigerI导管与6FJudkins导管在经挠动脉途径冠状动脉造影中的对比[J]. 安徽医药,2013,17(3):424-425.
[9] GENSINI G G. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol,1983,51(3):606.
[10] MANGIERI E,MACCHIARELLI G,CIAVOLELLA M,et al. Slow coronary flow:clinical and histopathological features in patients with otherwise normal epicardial coronary arteries[J]. Cathet Cardiovasc Diagn,1996,37(4):375-381.
[11] 周子凡,王龙飞,董松坡,等. 生物瓣膜置换术联合托拉塞米治疗心脏瓣膜病的效果及对B型脑钠肽和脂蛋白相关磷脂酶A2水平的影响[J]. 中国医药,2019,14(1):45-49.
[12] LV S L,ZENG Z F,GAN W Q,et al. Lp-PLA2 inhibition prevents Ang Ⅱ-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation[J]. Acta Pharmacol Sin,2021 ,42(12):2016-2032.
[13] MOUROUZIS K,SIASOS G,OIKONOMOU E,et al. Lipoprotein-associated phospholipase A2 levels,endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease[J]. Lipids Health Dis,2021,20(1):12.
[14] MA S,DING L,CAI M,et al. Association Lp-PLA2 gene poly-morphisms with coronary heart disease[J]. Dis Markers,2022,2022:9775699.
[15] 方顺淼,葛兴利,李运田,等. 脂蛋白相关磷脂酶A2和心型脂肪酸结合蛋白诊断急性心肌梗死的价值及与预后的关系[J]. 中华老年心脑血管病杂志,2022,24(2):148-150.
[16] MOUROUZIS K,SIASOS G,OIKONOMOUE,et al. Lipoprotein associated phospholipase A2 levels,endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease[J]. Lipids Health Dis,2021,20(1):12.
[17] 杨晴,刘彦虹. 细胞自噬与动脉粥样硬化关系的研究进展[J]. 国际免疫学杂志,2017,40:(3):309-312.
[18] ZHANG H,ZHOU W,CAO C,et al. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40[J]. PLoS One,2018 ,13(8):e0202797.
[19] SVAROVSKAYA A V,TEPLYAKOV A T,GUSAKOVA A M,et al. Role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome after coronary stenting[J]. Kardiologiia,2020,60(8):98-105.
[20] 牛泽家馨,王丹,胡桂霖,等. 单核细胞/高密度脂蛋白胆固醇比值与不稳定型心绞痛患者冠状动脉病变狭窄程度的相关性研究[J]. 西安交通大学学报(医学版),2023,44(1):14-21.
[21] 汪洋,李彩荣,王宁夫. 平均血小板容积和Gensini积分对急性ST 段抬高型心肌梗死患者PCI术后预后的影响[J]. 临床和实验医学杂志,2018,17(6):602-604.
[1]王娜,刘蕾,杜林翔,等.ACS患者血清FSTL-1、外周血淋巴细胞中PPAR-γ、MMP-9与冠状动脉狭窄程度的关系[J].天津医科大学学报,2021,27(04):325.
WANG Na,LIU Lei,DU Lin-xiang,et al.Relationship between serum FSTL-1,PPAR-γ,MMP-9 in peripheral blood lymphocytes and coronary stenosis in patients with ACS[J].Journal of Tianjin Medical University,2021,27(02):325.